Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?

Jillella AP, Ustun C.

Stem Cells Dev. 2004 Dec;13(6):598-606.

PMID:
15684827
3.

CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.

Kasow KA, Sims-Poston L, Eldridge P, Hale GA.

Biol Blood Marrow Transplant. 2007 May;13(5):608-14. Epub 2007 Mar 23.

4.

CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation.

Lanza F, Campioni D, Moretti S, Dominici M, Punturieri M, Focarile E, Pauli S, Dabusti M, Tieghi A, Bacilieri M, Scapoli C, De Angeli C, Galluccio L, Castoldi G.

Exp Hematol. 2001 Dec;29(12):1484-93.

PMID:
11750108
5.
6.

Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation.

Lee S, Kim S, Kim H, Baek EJ, Jin H, Kim J, Kim HO.

Vox Sang. 2008 Feb;94(2):146-52. Epub 2007 Nov 19.

PMID:
18028260
7.

Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.

Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B.

Blood. 1995 Jan 15;85(2):588-96. Review.

8.

Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation.

Pérez-Simón JA, Caballero MD, Corral M, Nieto MJ, Orfao A, Vazquez L, Amigo ML, Berges C, González M, Del Cañizo C, San Miguel JF.

Transfusion. 1998 Apr;38(4):385-91.

PMID:
9595022
9.
10.

Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.

Michallet M, Philip T, Philip I, Godinot H, Sebban C, Salles G, Thiebaut A, Biron P, Lopez F, Mazars P, Roubi N, Leemhuis T, Hanania E, Reading C, Fine G, Atkinson K, Juttner C, Coiffier B, Fière D, Archimbaud E.

Exp Hematol. 2000 Jul;28(7):858-70.

PMID:
10907648
11.

Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation.

Pérez-Simón JA, Martín A, Caballero D, Corral M, Nieto MJ, Gonzalez M, Vazquez L, López-Berges C, Cañizo MC, Mateos MV, Orfao A, San Miguel JF.

Bone Marrow Transplant. 1999 Dec;24(12):1279-83.

12.

Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.

Wallington-Beddoe CT, Gottlieb DJ, Garvin F, Antonenas V, Sartor MM.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1386-93. doi: 10.1016/j.bbmt.2009.06.018. Epub 2009 Aug 19.

13.

Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.

Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH.

Bone Marrow Transplant. 2002 Jun;29(12):967-72.

14.

Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.

Koç ON, Gerson SL, Phillips GL, Cooper BW, Kutteh L, Van Zant G, Reece DE, Fox RM, Schupp JE, Tainer N, Lazarus HM.

Bone Marrow Transplant. 1998 Feb;21(4):337-43.

15.

Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.

Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L, Masia CM, Centurioni R, Mancini S, Brunori M, Leoni P.

Haematologica. 1998 Apr;83(4):329-37.

16.

The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue.

Millar BC, Millar JL, Shepherd V, Blackwell P, Porter H, Cunningham D, Judson I, Treleaven J, Powles RL, Catovsky D.

Bone Marrow Transplant. 1998 Sep;22(5):469-75.

17.

Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation.

Sartor MM, Garvin F, Antonenas V, Bradstock KF, Gottlieb DJ.

Bone Marrow Transplant. 2007 Nov;40(9):851-7. Epub 2007 Aug 20.

PMID:
17704793
18.

[CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].

Sawada H, Wake A, Yamasaki Y, Izumi Y.

Rinsho Ketsueki. 2000 Jun;41(6):500-6. Japanese.

PMID:
10921350
19.

Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation.

Meldgaard Knudsen L, Jensen L, Jarlbaek L, Hansen PG, Hansen SW, Drivsholm L, Nikolaisen K, Gaarsdal E, Johnsen HE.

Haematologica. 1999 Jun;84(6):517-24.

20.

Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.

Finke J, Brugger W, Bertz H, Behringer D, Kunzmann R, Weber-Nordt RM, Kanz L, Mertelsmann R.

Bone Marrow Transplant. 1996 Dec;18(6):1081-6.

PMID:
8971376

Supplemental Content

Support Center